article thumbnail

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Drug Discovery World

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18

Licensing 246
article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. DDW’s Megan Thomas explores three trends in the market. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Marketing 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Positive data for 4SC’s CTCL treatment fuels marketing strategy  

Drug Discovery World

Our focus in the near term is on the registration, approval and commercialization of Kinselby in the European Union, Switzerland and the UK and we are on track to file for European Marketing Approval of Kinselby in Q1 2024, to rapidly bring this therapy into clinical use. 4SC is

Marketing 130
article thumbnail

Buoyant UK biotech sector secures £1.8bn investment in 2023

Drug Discovery World

There were no new market launches due to continued low valuations and investor appetite, however, two European listings on Nasdaq signals a gradual recovery. Major licensing and M&A deals demonstrate the ongoing quality and attractiveness of UK science.

Licensing 130
article thumbnail

Avacta Announces License Agreement With POINT Biopharma Inc.

The Pharma Data

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

article thumbnail

TG shares tumble following licensing deal for MS drug

BioPharma Drive: Drug Pricing

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

article thumbnail

UK’S MHRA GRANTS MARKETING AUTHORISATION FOR PFIZER’S CIBINQO® (ABROCITINIB) FOR.

The Pharma Data

This is the first marketing authorization globally for abrocitinib-. This is the first marketing authorization globally for abrocitinib-. Abrocitinib is licensed in Great Britain in recommended doses of 100mg and 200mg. This is the first marketing authorization worldwide for this treatment. “We